Trial reportResearch and practice in thrombosis and haemostasis2026
Quality of life and functional recovery after venous stent placement for postthrombotic syndrome: insights from the ARIVA multinational randomized trial.
Trial report in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postthrombotic syndrome (PTS) is a disabling complication of deep vein thrombosis and is associated with impaired functional status. Objectives: To assess the impact of stent placement for post-thrombotic syndrome on functional outcomes and quality of life. Methods: The Aspirin Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis Among Patients with Postthrombotic Syndrome trial was a multinational, randomized study comparing rivaroxaban plus aspirin vs rivaroxaban monotherapy after venous revascularization for PTS. The Villalta score and the Chronic Venous Insufficiency Quality of Life Questionnaire-20 (CIVIQ-20) were assessed at randomization and during 6-month follow-up. A multivariable mixed-effects model was used to identify predictors of quality of life (QoL). Results: Of 149 enrolled patients, 55% had moderate-to-severe PTS at baseline, according to the Villalta score. Compared with patients with mild PTS, they were characterized by longer stent segments, higher body mass index, and were more frequently smokers. The 6-month primary patency rate was similar between groups: 91.5% vs 95.5%, respectively. The improvement in PTS severity consisted of an overall mean reduction of -6.5 (SD 4.6) points, corresponding to a change of -8.5 (5.0) points among patients with moderate-to-severe PTS and -4 (2.6) points among patients with mild PTS after 6 months. Median CIVIQ-20 scores were lower, indicating worse QoL, among patients with moderate-to-severe PTS compared with mild PTS, consistently at baseline and all follow-up timepoints. Female sex and greater PTS severity were independently associated with worse QoL after adjustment for age, body mass index, treatment group, adverse events, and timepoint. Conclusion: Over the 6 months after endovascular treatment accessory to standard care for PTS, both PTS severity measured by the Villalta score and QoL measured by CIVIQ-20 improved. However, greater PTS severity and female sex were independently associated with worse QoL outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.